GOSS: NDA filing for seralutinib is imminent, with strong clinical data and broad label prospects
The team is preparing an NDA for seralutinib following positive FDA feedback and strong phase III and subgroup data, especially in CTD-associated PAH. Broad label approval is anticipated, with rapid commercial uptake expected due to favorable safety and efficacy, and future pipeline expansion plann…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.